Atrial-selective sodium channel block by dronedarone: Sufficient to terminate atrial fibrillation?

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 384, Issue 2, 2011, Pages 109-114

  Ehrlich, Joachim R ^a   Dobrev, Dobromir ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DRONEDARONE; RANOLAZINE; SODIUM CHANNEL;

ACTION POTENTIAL; DRUG EFFICACY; DRUG INHIBITION; HEART ATRIUM FIBRILLATION; HEART REPOLARIZATION; HUMAN; MEMBRANE STEADY POTENTIAL; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; SODIUM CURRENT;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; HUMANS; MALE;

EID: 79961166764     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0647-5     Document Type: Review

References (34)

1. R Bogdan H Goegelein H Ruetten 2011 Effect of dronedarone on Na+, Ca2+ and HCN channels Naunyn Schmiedebergs Arch of Pharmacol 383 4 347 356 10.1007/s00210-011-0599-9 1:CAS:528:DC%2BC3MXis1yjsrs%3D
2. A Burashnikov C Antzelevitch 2010 New developments in atrial antiarrhythmic drug therapy Nat Rev Cardiol 7 3 139 148 20179721 10.1038/nrcardio.2009.245 1:CAS:528:DC%2BC3cXitlSnsro%3D
3. A Burashnikov JM Di Diego AC Zygmunt L Belardinelli C Antzelevitch 2007 Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine Circulation 116 13 1449 1457 17785620 10.1161/CIRCULATIONAHA.107.704890 1:CAS:528:DC%2BD2sXhtVKiu7rE (Pubitemid 47480635)
4. A Burashnikov L Belardinelli C Antzelevitch 2010 Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria Heart Rhythm 7 9 1273 1279 20478403 10.1016/j.hrthm.2010.05.019
5. B Burstein S Nattel 2008 Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation J Am Coll Cardiol 51 8 802 809 18294563 10.1016/j.jacc.2007.09.064 1:CAS:528:DC%2BD1cXitlequ7s%3D (Pubitemid 351260071)
6. AJ Camm P Kirchhof GY Lip U Schotten I Savelieva S Ernst IC Van Gelder AN Al G Hindricks B Prendergast H Heidbuchel O Alfieri A Angelini D Atar P Colonna R De Caterina J De Sutter A Goette B Gorenek M Heldal SH Hohloser P Kolh JY Le Heuzey P Ponikowski FH Rutten 2010 Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 19 2369 2429 20802247 10.1093/eurheartj/ehq278
7. A Capucci G Boriani GL Botto T Lenzi I Rubino C Falcone G Trisolino CS Della N Binetti M Cavazza 1994 Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide Am J Cardiol 74 5 503 505 8059737 10.1016/0002-9149(94)90915-6 1:STN:280:DyaK2czjslOgtQ%3D%3D (Pubitemid 24269976)
8. S Dhein A Hagen J Jozwiak A Dietze J Garbade M Barten M Kostelka FW Mohr 2010 Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides Naunyn Schmiedebergs Arch Pharmacol 381 3 221 234 19943035 10.1007/s00210-009-0473-1 1:CAS:528: DC%2BC3cXlvVOnu74%3D
9. D Dobrev 2006 Electrical remodeling in atrial fibrillation Herz 31 2 108 112 16738832 10.1007/s00059-006-2787-9 (Pubitemid 43899995)
10. D Dobrev S Nattel 2010 New antiarrhythmic drugs for treatment of atrial fibrillation Lancet 375 9721 1212 1223 20334907 10.1016/S0140-6736(10)60096-7 1:CAS:528:DC%2BC3cXktlGitrw%3D
11. D Dobrev A Friedrich N Voigt N Jost E Wettwer T Christ M Knaut U Ravens 2005 The G protein-gated potassium current I(K, ACh) is constitutively active in patients with chronic atrial fibrillation Circulation 112 24 3697 3706 16330682 10.1161/CIRCULATIONAHA.105.575332 1:CAS:528:DC%2BD2MXht1yitb7P (Pubitemid 43739509)
12. M Duytschaever Y Blaauw M Allessie 2005 Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs Cardiovasc Res 67 1 69 76 15949471 10.1016/j.cardiores.2005.02.019 1:CAS:528:DC%2BD2MXltFSru74%3D (Pubitemid 40803460)
13. JR Ehrlich S Nattel 2009 Novel approaches for pharmacological management of atrial fibrillation Drugs 69 7 757 774 19441867 10.2165/00003495-200969070- 00001 1:CAS:528:DC%2BD1MXosVarsLg%3D
14. JR Ehrlich S Nattel SH Hohnloser 2002 Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets J Cardiovasc Electrophysiol 13 4 399 405 12033360 10.1046/j.1540-8167.2002.00399.x (Pubitemid 34407608)
15. JR Ehrlich TJ Cha L Zhang D Chartier P Melnyk SH Hohnloser S Nattel 2003 Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties J Physiol 551 Pt 3 801 813 12847206 10.1113/jphysiol.2003.046417 1:CAS:528:DC%2BD3sXosFOhsro%3D (Pubitemid 37221074)
16. N Gaborit M Steenman G Lamirault N Le Meur S Le Bouter G Lande J Leger F Charpentier T Christ D Dobrev D Escande S Nattel S Demolombe 2005 Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation Circulation 112 4 471 481 16027256 10.1161/CIRCULATIONAHA.104.506857 (Pubitemid 41060786)
17. J Gierten E Ficker R Bloehs PA Schweizer E Zitron E Scholz C Karle HA Katus D Thomas 2010 The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone Naunyn Schmiedebergs Arch Pharmacol 381 3 261 270 19777211 10.1007/s00210-009-0454-4 1:CAS:528:DC%2BC3cXlvVOnu70%3D
18. Z Girmatsion P Biliczki A Bonauer G Wimmer-Greinecker M Scherer A Moritz A Bukowska A Goette S Nattel SH Hohnloser JR Ehrlich 2009 Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation Heart Rhythm 6 12 1802 1809 19959133 10.1016/j.hrthm.2009.08.035
19. SH Hohnloser HJ Crijns M van Eickels C Gaudin RL Page C Torp-Pedersen SJ Connolly 2009 Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 360 7 668 678 19213680 10.1056/NEJMoa0803778 1:CAS:528:DC%2BD1MXhvVyisbg%3D
20. Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, Yin H, Knollmann BC (2011) Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol (in press)
21. A Jahangir V Lee PA Friedman JM Trusty DO Hodge SL Kopecky DL Packer SC Hammill WK Shen BJ Gersh 2007 Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study Circulation 115 24 3050 3056 17548732 10.1161/CIRCULATIONAHA.106.644484 (Pubitemid 46956493)
22. J Jalife O Berenfeld M Mansour 2002 Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation Cardiovasc Res 54 2 204 216 12062327 10.1016/S0008-6363(02)00223-7 1:CAS:528:DC%2BD38XivF2qs7g%3D (Pubitemid 34327901)
23. J Kneller J Leon S Nattel 2001 How do class 1 antiarrhythmic drugs terminate atrial fibrillation? A quantitative analysis based on a realistic ionic model Circulation 104 17 5 5
24. S Nattel B Burstein D Dobrev 2008 Atrial remodeling and atrial fibrillation: mechanisms and implications Circ Arrhythm Electrophysiol 1 1 62 73 19808395 10.1161/CIRCEP.107.754564
25. K Nishida XY Qi R Wakili P Comtois D Chartier M Harada YK Iwasaki P Romeo A Maguy D Dobrev G Michael M Talajic S Nattel 2011 Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model Circulation 123 2 137 146 21200008 10.1161/CIRCULATIONAHA.110.972778 1:CAS:528:DC%2BC3MXnsVSntw%3D%3D
26. U Schotten S Verheule P Kirchhof A Goette 2011 Pathophysiological mechanisms of atrial fibrillation: a translational appraisal Physiol Rev 91 1 265 325 21248168 10.1152/physrev.00031.2009
27. K Shinagawa A Shiroshita-Takeshita G Schram S Nattel 2003 Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone Circulation 107 10 1440 1446 12642367 10.1161/01.CIR.0000055316.35552.74 1:CAS:528:DC%2BD3sXhslGjsb4%3D (Pubitemid 36350745)
28. S Sicouri A Burashnikov L Belardinelli C Antzelevitch 2010 Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria Circ Arrhythm Electrophysiol 3 1 88 95 19952329 10.1161/CIRCEP.109.886275 1:CAS:528:DC%2BC3cXjvFCmt7s%3D
29. S Sossalla B Kallmeyer S Wagner M Mazur U Maurer K Toischer JD Schmitto R Seipelt FA Schondube G Hasenfuss L Belardinelli LS Maier 2010 Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium J Am Coll Cardiol 55 21 2330 2342 20488304 10.1016/j.jacc.2009.12.055 1:CAS:528:DC%2BC3cXosVWrsrw%3D
30. MJ Suttorp JH Kingma LA Huen EG Mast 1989 Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm Am J Cardiol 63 11 693 696 2493733 10.1016/0002-9149(89)90253-1 1:STN:280:DyaL1M7msVWlug%3D%3D (Pubitemid 19080350)
31. P Touboul J Brugada A Capucci HJ Crijns N Edvardsson SH Hohnloser 2003 Dronedarone for prevention of atrial fibrillation: a dose-ranging study Eur Heart J 24 16 1481 1487 12919771 10.1016/S0195-668X(03)00321-X 1:CAS:528:DC%2BD3sXmt1Wqu7k%3D (Pubitemid 37010577)
32. DR van Wagoner AL Pond M Lamorgese SS Rossie PM McCarthy JM Nerbonne 1999 Atrial L-type Ca currents and human atrial fibrillation Circ Res 85 428 436 10473672 (Pubitemid 29409619)
33. N Voigt N Rozmaritsa A Trausch T Zimniak T Christ E Wettwer K Matschke D Dobrev U Ravens 2010 Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation Naunyn Schmiedebergs Arch Pharmacol 381 3 251 259 19760273 10.1007/s00210-009-0452-6 1:CAS:528:DC%2BC3cXlvVOnurc%3D
34. MC Wijffels CJ Kirchhof R Dorland MA Allessie 1995 Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats Circulation 92 1954 1968 7671380 1:STN:280:DyaK2MvgtFemtg%3D%3D